Physician profile
Darin D Thomas
NPI 1508967738
$6,494.90
in general payments reported to CMS, 2019-2025
39 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.81 · 2021: $859 · 2022: $1,161 · 2023: $1,032 · 2024: $1,548 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,450.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,063.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $738.51 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $674.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $505.47 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $293.28 | 2021-2025 | |
| Amgen INC. | $285.06 | 2021-2025 | Repatha, Repatha, Evenity |
| Glaxosmithkline, LLC. | $265.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $206.25 | 2021-2023 | Xarelto |
| Mylan Specialty L.P. | $200.68 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.44 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $185.06 | 2022-2025 | |
| Abbott Laboratories | $161.14 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $158.52 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $154.93 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.30 | 2023-2025 | Caplyta |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.